JP4101876B2 - 抗炎症活性を有する脂質抽出物 - Google Patents
抗炎症活性を有する脂質抽出物 Download PDFInfo
- Publication number
- JP4101876B2 JP4101876B2 JP51149997A JP51149997A JP4101876B2 JP 4101876 B2 JP4101876 B2 JP 4101876B2 JP 51149997 A JP51149997 A JP 51149997A JP 51149997 A JP51149997 A JP 51149997A JP 4101876 B2 JP4101876 B2 JP 4101876B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- oil
- lipid extract
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims description 34
- 150000002632 lipids Chemical class 0.000 title claims description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 32
- 206010003246 arthritis Diseases 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 14
- 239000004006 olive oil Substances 0.000 claims description 14
- 235000008390 olive oil Nutrition 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 13
- 241001537210 Perna Species 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 6
- 229960005233 cineole Drugs 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- 229930007050 cineol Natural products 0.000 claims description 3
- 239000010776 emu oil Substances 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 125000003555 cineol group Chemical group 0.000 claims 1
- 241000237536 Mytilus edulis Species 0.000 description 25
- 235000020638 mussel Nutrition 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241001537211 Perna canaliculus Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 239000000679 carrageenan Substances 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229940113118 carrageenan Drugs 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010036030 Polyarthritis Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000030428 polyarticular arthritis Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 230000002456 anti-arthritic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 free fatty acids Chemical class 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 231100000420 gastrotoxicity Toxicity 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- UGOFYAXVVVXMQT-UHFFFAOYSA-N clobuzarit Chemical compound C1=CC(COC(C)(C)C(O)=O)=CC=C1C1=CC=C(Cl)C=C1 UGOFYAXVVVXMQT-UHFFFAOYSA-N 0.000 description 1
- 229950007550 clobuzarit Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
- 229950000752 methylhexaneamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000010464 refined olive oil Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU5311 | 1983-08-10 | ||
| AUPN5311A AUPN531195A0 (en) | 1995-09-11 | 1995-09-11 | Lipid extract having anti-inflamatory activity |
| PCT/AU1996/000564 WO1997009992A1 (en) | 1995-09-11 | 1996-09-10 | Lipid extract having anti-inflammatory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH11512400A JPH11512400A (ja) | 1999-10-26 |
| JPH11512400A5 JPH11512400A5 (enExample) | 2004-09-16 |
| JP4101876B2 true JP4101876B2 (ja) | 2008-06-18 |
Family
ID=3789640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51149997A Expired - Lifetime JP4101876B2 (ja) | 1995-09-11 | 1996-09-10 | 抗炎症活性を有する脂質抽出物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6083536A (enExample) |
| EP (1) | EP0850068B1 (enExample) |
| JP (1) | JP4101876B2 (enExample) |
| AT (1) | ATE293984T1 (enExample) |
| AU (1) | AUPN531195A0 (enExample) |
| CA (1) | CA2231803C (enExample) |
| DE (1) | DE69634666T2 (enExample) |
| DK (1) | DK0850068T3 (enExample) |
| ES (1) | ES2241001T3 (enExample) |
| PT (1) | PT850068E (enExample) |
| WO (1) | WO1997009992A1 (enExample) |
| ZA (1) | ZA967626B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220131272A (ko) | 2020-01-21 | 2022-09-27 | 린트벨스 리미티드 | 상승효과가 있는 조성물 |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
| JP2002502311A (ja) | 1997-06-04 | 2002-01-22 | セルラー インプルーブメンツ リミテッド | 生物材料の破砕のための方法および装置 |
| SE9703085D0 (sv) * | 1997-08-27 | 1997-08-27 | Micro Active Protein In Sweden | Anti-microbial composition |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| US7220427B2 (en) | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
| DE19838794A1 (de) * | 1998-08-26 | 2000-03-09 | Aristavet Veterinaerspezialita | Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels |
| AUPP910699A0 (en) * | 1999-03-10 | 1999-04-01 | Pharmalink International Limited | Inhibitor of lipoxygenase pathways |
| AU2005200953B2 (en) * | 1999-03-22 | 2007-07-12 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| US6596303B1 (en) * | 1999-03-22 | 2003-07-22 | Mars Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| US20020018787A1 (en) * | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| DE60038320D1 (de) * | 1999-07-21 | 2008-04-24 | Bomac Research Ltd | Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen |
| WO2001013956A2 (en) * | 1999-08-26 | 2001-03-01 | Ganeden Biotech, Inc. | Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| AU9347701A (en) * | 2000-09-22 | 2002-04-02 | Pharmalink Internat Ltd | Immunomodulatory preparation |
| US7519546B2 (en) * | 2001-04-30 | 2009-04-14 | General Electric Company | Maintaining synchronization of information published to multiple subscribers |
| DK1417211T3 (da) | 2001-07-27 | 2007-10-08 | Neptune Technologies & Bioress | Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse |
| AUPS082102A0 (en) * | 2002-03-01 | 2002-03-21 | Women's And Children's Hospital | Therapeutic properties of oils |
| AU2003222002A1 (en) * | 2002-03-14 | 2003-09-29 | Jackie H. Mcclung | Pharmaceutically active compounds containing phosphorous defficient oil |
| DE20210182U1 (de) * | 2002-07-01 | 2002-10-02 | Bio-Innovation Development Ltd., Christchurch | Wirkstoffzusammensetzung aus Bestandteilen der Grünlippenmuschel (perna canaliculus) und zusätzlichen Omega-3-Fettsäuren |
| JP2006520389A (ja) * | 2003-03-14 | 2006-09-07 | フードサイエンス、コーポレイション | Ｐｅｒｎａｃａｎａｌｉｃｕｌｕｓ成分およびｐｅｒｎａｃａｎａｌｉｃｕｌｕｓエキスを用いる癌の処置方法 |
| US7052715B2 (en) * | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| CA2554932A1 (en) * | 2004-01-30 | 2005-08-11 | Bionovate Limited | Solvent extraction of lipids such as essential fatty acids |
| GB0411165D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Hyaluronic acid containing pharmaceutical or veterinary compounds |
| GB0411166D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
| US20060039992A1 (en) * | 2004-06-02 | 2006-02-23 | Miller Bruce A Jr | Novel compositions and methods utilizing green-lipped mussel and fatty acids |
| WO2006052150A1 (en) * | 2004-11-15 | 2006-05-18 | University Of Otago | Mussel extract composition with enhanced anti-inflammatory activity |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| NZ563125A (en) * | 2005-06-03 | 2009-11-27 | Mcfarlane Marketing Aust Pty L | Lipid extract of mussels and method for preparation thereof |
| NZ547429A (en) * | 2006-05-24 | 2009-09-25 | Ind Res Ltd | Extraction of highly unsaturated lipids with liquid dimethyl ether |
| US20090238763A1 (en) * | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| HUE033687T2 (en) | 2006-07-18 | 2017-12-28 | Techfields Biochem Co Ltd | Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates |
| PL2046727T3 (pl) | 2006-07-25 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę |
| PT2049482E (pt) | 2006-08-08 | 2016-02-24 | Techfields Biochem Co Ltd | Profármacos solúveis em água carregados positivamente de ácidos aril- e heteroarilacéticos com velocidade de penetração na pele muito rápida |
| PL2084132T3 (pl) | 2006-09-03 | 2019-03-29 | Techfields Biochem Co. Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry |
| EP3388417A1 (en) | 2006-09-03 | 2018-10-17 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
| WO2008035756A1 (en) * | 2006-09-22 | 2008-03-27 | Heimat Co., Ltd. | Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin |
| CA2665081C (en) * | 2006-10-02 | 2015-12-01 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
| EP2084165B1 (en) | 2006-10-11 | 2013-06-12 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate |
| NZ552238A (en) * | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
| WO2008146298A1 (en) * | 2007-06-01 | 2008-12-04 | Ganga Raju Gokaraju | Use of aphanamixis polystacha extracts or fractions against 5 -lipoxygenase mediated diseases |
| JP2010529101A (ja) * | 2007-06-04 | 2010-08-26 | テックフィールズ インコーポレイテッド | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 |
| AU2008355537B2 (en) * | 2008-04-28 | 2014-02-06 | 21 Holding Sas Di Monico Cav. Silvano | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide |
| CN108191846B (zh) | 2008-12-04 | 2021-08-20 | 于崇曦 | 高穿透性组合物及其应用 |
| JP5313064B2 (ja) * | 2009-07-03 | 2013-10-09 | 株式会社ノエビア | 中性脂肪蓄積促進剤、豊胸剤 |
| HK1207562A1 (en) | 2012-01-18 | 2016-02-05 | 苏州泰飞尔医药有限公司 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| EP2938324B1 (en) | 2012-12-31 | 2023-11-08 | JRX Biotechnology, Inc. | Liquid topical pharmaceutical nano-emulsion formulations |
| JP6176655B2 (ja) * | 2013-07-02 | 2017-08-09 | 御木本製薬株式会社 | マトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤、老化防止用皮膚外用剤、シワ防止用皮膚外用剤、慢性関節リウマチ及び他の疾患の治療又は予防剤 |
| BR112018000953A2 (pt) * | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| EP3349717A4 (en) | 2015-09-17 | 2019-04-17 | JRX Biotechnology, Inc. | APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION |
| AU2017380470B2 (en) * | 2016-12-20 | 2022-12-22 | Sanford Limited | Method of processing shellfish and resulting compositions |
| CN111432654A (zh) * | 2017-12-04 | 2020-07-17 | 雾凇科技有限公司 | 从甲壳类捕获物中生产蛋白质磷脂复合物的方法 |
| NZ755776A (en) * | 2017-12-22 | 2020-05-29 | Pharmalink International Ltd | Lipid combinations |
| US12604918B2 (en) | 2020-01-21 | 2026-04-21 | Lintbells Limited | Synergistic compositions |
| CN113041263B (zh) * | 2021-03-15 | 2023-07-25 | 青岛大学 | 一种贻贝功能性脂质在制备治疗2型糖尿病产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0010061B1 (en) * | 1978-09-25 | 1983-07-13 | Stuart John Mc Farlane | Pharmaceutical preparations containing a mollusc extract |
| US4801453A (en) | 1984-05-01 | 1989-01-31 | James M. Broadbent | Stabilized mussel extract |
| AUPM740594A0 (en) | 1994-08-11 | 1994-09-01 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AU3156595A (en) * | 1994-08-11 | 1996-03-07 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
-
1995
- 1995-09-11 AU AUPN5311A patent/AUPN531195A0/en not_active Abandoned
-
1996
- 1996-09-10 CA CA002231803A patent/CA2231803C/en not_active Expired - Lifetime
- 1996-09-10 PT PT96929129T patent/PT850068E/pt unknown
- 1996-09-10 ES ES96929129T patent/ES2241001T3/es not_active Expired - Lifetime
- 1996-09-10 US US09/029,957 patent/US6083536A/en not_active Expired - Lifetime
- 1996-09-10 DE DE69634666T patent/DE69634666T2/de not_active Expired - Lifetime
- 1996-09-10 EP EP96929129A patent/EP0850068B1/en not_active Expired - Lifetime
- 1996-09-10 WO PCT/AU1996/000564 patent/WO1997009992A1/en not_active Ceased
- 1996-09-10 ZA ZA9607626A patent/ZA967626B/xx unknown
- 1996-09-10 DK DK96929129T patent/DK0850068T3/da active
- 1996-09-10 AT AT96929129T patent/ATE293984T1/de active
- 1996-09-10 JP JP51149997A patent/JP4101876B2/ja not_active Expired - Lifetime
-
2000
- 2000-07-05 US US09/610,484 patent/US6346278B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220131272A (ko) | 2020-01-21 | 2022-09-27 | 린트벨스 리미티드 | 상승효과가 있는 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| AUPN531195A0 (en) | 1995-10-05 |
| JPH11512400A (ja) | 1999-10-26 |
| US6083536A (en) | 2000-07-04 |
| ATE293984T1 (de) | 2005-05-15 |
| CA2231803A1 (en) | 1997-03-20 |
| DK0850068T3 (da) | 2005-08-15 |
| ES2241001T3 (es) | 2005-10-16 |
| EP0850068B1 (en) | 2005-04-27 |
| EP0850068A4 (en) | 2000-09-13 |
| CA2231803C (en) | 2004-11-23 |
| ZA967626B (en) | 1997-09-03 |
| WO1997009992A1 (en) | 1997-03-20 |
| EP0850068A1 (en) | 1998-07-01 |
| PT850068E (pt) | 2005-08-31 |
| US6346278B1 (en) | 2002-02-12 |
| DE69634666D1 (de) | 2005-06-02 |
| DE69634666T2 (de) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6083536A (en) | Super-critical lipid extract from mussels having anti-inflammatory activity | |
| RU2122409C1 (ru) | Лечение жирными кислотами | |
| EP0440341B1 (en) | EFA compositions and therapy | |
| US4874794A (en) | Inflammatory disease treatment | |
| Gutiérrez et al. | Hepatoprotective and inhibition of oxidative stress in liver of Prostechea michuacana | |
| EP0189788B1 (de) | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika | |
| JPS61215322A (ja) | γ‐リノレン酸またはジホモ‐γ‐リノレン酸の使用方法 | |
| NZ227241A (en) | Pharmaceutical compositions comprising a cyclosporin and either dihomo-gamma or gamma-linolenic acid and use in combatting the effects of cyclosporin administration | |
| US20140107206A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| EP0560806A1 (en) | Anti-inflammatory composition derived from emu oil | |
| EP0524796B1 (en) | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS | |
| JPS6229511A (ja) | ミクロエマルジヨン組成物 | |
| DE3907649C2 (de) | Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung | |
| JP2011067213A (ja) | 生物活性油 | |
| JPH04505758A (ja) | 即効で増強された解熱応答 | |
| AU616502B2 (en) | Treatment of inflammatory disorders in humans | |
| US5194451A (en) | Systemic anti-inflammatory treatment | |
| US5166219A (en) | Systemic anti-inflammatory treatment | |
| CN105407885A (zh) | 包含ω-3脂肪酸和番茄的番茄红素的组合 | |
| US20080274209A1 (en) | Methods of treating inflammation | |
| KR960700064A (ko) | 아연이 보충된 전립선 추출물 | |
| US5260067A (en) | Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same | |
| JP2018039769A (ja) | ウロリチン類を含有する前駆脂肪細胞分化抑制剤 | |
| Schulz et al. | Effects of acetylsalicylic acid on ascorbic acid concentrations in plasma, gastric mucosa, gastric juice and urine--a double-blind study in healthy subjects | |
| AU703368B2 (en) | Lipid extract having anti-inflammatory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080321 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120328 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140328 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |